<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03669718</url>
  </required_header>
  <id_info>
    <org_study_id>ISA101b-HN-01-17</org_study_id>
    <nct_id>NCT03669718</nct_id>
  </id_info>
  <brief_title>A Randomized Phase 2 Study of Cemiplimab ± ISA101b in HPV16-Positive OPC</brief_title>
  <official_title>A Randomized, Double-blind, Placebo-Controlled, Phase 2 Study of Cemiplimab Versus the Combination of Cemiplimab With ISA101b in the Treatment of Subjects With HPV16-Positive Oropharyngeal Cancer (OPC)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>ISA Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Regeneron Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>ISA Pharmaceuticals</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This will be a blinded, placebo-controlled, randomized, phase 2 study in which subjects will
      be randomly assigned 1:1 to cemiplimab plus placebo or cemiplimab plus ISA101b.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study will assess the ability of ISA101b to improve Overall Response Rate in subjects
      with HPV16 positive OPC, when combined with cemiplimab, an investigational anti-PD-1 antibody
      being developed by Regeneron Pharmaceuticals. ISA101b is a therapeutic cancer vaccine that
      induces specific immune responses to the oncogenic E6 and E7 antigens from HPV16. Trials in
      HPV16 driven malignancies indicate it has activity in HPV16 driven malignancies including
      oropharyngeal and cervical cancers. Cemiplimab, also known as REGN2810, is in late stage
      trials and appears to have similar activity to approved anti PD-1 antibodies in a number of
      malignancies .
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 30, 2018</start_date>
  <completion_date type="Anticipated">November 2022</completion_date>
  <primary_completion_date type="Anticipated">November 2020</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Overall Response Rate</measure>
    <time_frame>25months</time_frame>
    <description>Measured using RECIST 1.1</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of participants with treatment-related adverse events as assessed by NCI CTCAE v5.0 &quot;Number of participants with treatment-related adverse events as assessed by NCI CTCAE v5.0&quot;.</measure>
    <time_frame>25 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Duration of response (DOR) by independent review in subjects randomized to receive ISA101b plus cemiplimab compared to placebo plus cemiplimab.</measure>
    <time_frame>25months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">194</enrollment>
  <condition>Squamous Cell Carcinoma of the Oropharynx</condition>
  <condition>HPV16 Positive</condition>
  <arm_group>
    <arm_group_label>Active ISA101b and cemiplimab.</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>ISA101b 3 times plus cemiplimab every 3 weeks for up to 24 months</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo and cemiplimab</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo 3 times plus cemiplimab every 3 weeks for up to 24 months</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>ISA101b</intervention_name>
    <description>Every 3 weeks for a total of 3 times</description>
    <arm_group_label>Active ISA101b and cemiplimab.</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cemiplimab</intervention_name>
    <description>Every 3 weeks for up to 24 months</description>
    <arm_group_label>Active ISA101b and cemiplimab.</arm_group_label>
    <arm_group_label>Placebo and cemiplimab</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Every 3 weeks for a total of 3 times</description>
    <arm_group_label>Placebo and cemiplimab</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Males and females, ≥ 18 years of age.

          -  Sign and date an Institutional Review Board/Independent Ethics Committee
             (IRB)/(IEC)-approved written informed consent form (ICF) in accordance with regulatory
             and institutional guidelines. This must be obtained before the performance of any
             protocol-related procedures that are not part of normal subject care.

          -  Be willing and able to comply with scheduled visits, treatment schedule, laboratory
             testing, and other requirements of the study.

          -  Diagnosed with histologically confirmed recurrent or metastatic HPV16 positive OPC,
             whose tumors express PD-L1 (Combined Positive Score [CPS] ≥1) and who are candidates
             for first line therapy with an PD-1 blocking antibody, AND subjects with recurrent or
             metastatic HPV16 positive OPC with disease progression on or after platinum containing
             chemotherapy.

          -  HPV-16 genotyping will be determined by the specified central reference laboratory.

          -  Eastern Cooperative Oncology Group (ECOG) performance status of 0-1.

          -  Measurable disease by computed tomography (CT) or magnetic resonance imaging (MRI) per
             RECIST 1.1 criteria.

          -  Prior curative radiation therapy must have been completed at least 4 weeks prior to
             study drug administration. Prior focal palliative radiotherapy must have been
             completed at least 2 weeks before study drug administration.

          -  Women of childbearing potential (WOCBP) must have a negative serum or urine pregnancy
             test (minimum sensitivity 25 IU/L or equivalent units of human chorionic gonadotropin
             [HCG]) within 24 hours prior to the start of study drug.

        Exclusion criteria:

          -  Subjects with previously untreated metastatic or unresectable, recurrent HPV16
             positive OPC whose tumors do not express PD-L1 (CPS&lt;1) and who are therefore not
             candidates for monotherapy with an anti-PD-1 antibody.

          -  Subjects with known brain metastases or leptomeningeal metastases.

          -  Any serious or uncontrolled medical disorder that, in the opinion of the investigator,
             may increase the risk associated with study participation or study drug
             administration, impair the ability of the subject to receive protocol therapy, or
             interfere with the interpretation of study results.

          -  History of other malignancy ≤ 3 years prior to entry into this trial with the
             exception of basal cell or squamous cell skin carcinoma which were treated with local
             resection only, or carcinoma in situ of the cervix, prostate or breast, or low grade
             non-muscle invasive superficial bladder cancer (TaLG)/carcinoma in situ of the
             bladder.

          -  Subjects with active, known or suspected autoimmune disease. Subjects with vitiligo,
             type I diabetes mellitus, residual hypothyroidism due to autoimmune condition only
             requiring hormone replacement, psoriasis not requiring systemic treatment, or
             conditions not expected to recur in the absence of an external trigger are permitted
             to enroll.

          -  Subjects with a condition requiring immunosuppressive doses of systemic medication
             such as steroids or absorbed topical steroids (doses ≥ 10 mg/day prednisone or
             equivalent) or other immunosuppressive medications within 14 days of study drug
             administration. Inhaled or topical steroids and adrenal replacement doses &lt; 10 mg
             daily prednisone equivalents are permitted in the absence of active autoimmune
             disease.

          -  Prior treatment with an anti-PD-1 antibody (e.g., nivolumab, pembrolizumab,
             cemiplimab), as well as an antibody targeting anti-PL-L1 anti-PD-L2, anti-CTLA-4
             antibody, or any other antibody or drug specifically targeting T-cell co stimulation
             or immune checkpoint pathways.

          -  Prior treatment with more than one chemotherapy regimen for the management of
             metastatic OPC.

          -  Prior treatment with therapeutic anti-HPV vaccines including ISA101 or ISA101b.
             Subjects may have received a preventive HPV vaccine.

          -  All toxicities attributed to systemic prior anti-cancer therapy other than alopecia
             and fatigue must have resolved to Grade 1 (NCI CTCAE) or baseline before
             administration of study drug. Subjects with toxicities attributed to systemic prior
             anticancer therapy that are not expected to resolve and result in long lasting
             sequelae, such as neuropathy after platinum based therapy, are permitted to enroll.

          -  History of allergy to ISA101/ISA101b study drug components, e.g., ISA101/101b,
             Montanide, or Macrogolglycerol Ricinoleate, also known as cremophore.

          -  History of allergy to cemiplimab and its excipients.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bonnie S. Glisson, MD, BS</last_name>
    <role>Principal Investigator</role>
    <affiliation>M.D. Anderson Cancer Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Sonja Visscher</last_name>
    <phone>+31713322310</phone>
    <email>Visscher@isa-pharma.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>City of Hope</name>
      <address>
        <city>Duarte</city>
        <state>California</state>
        <zip>91010</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Erminia Massarelli, MD, PhD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Moores Cancer Center at the UC San Diego Health</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92093</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kathryn Gold, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of California San Francisco</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94115</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alain Algazi, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Robert H. Lurie Comprehensive Cancer Center</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60208</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mark Agulnik, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Cincinnati Cancer Institute</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45069</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Muhammad Kashif Riaz, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>UPMC Hillman Cancer Center</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15232</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Daniel Zandberg, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>M. D. Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Bonnie Glisson, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Washington</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98195</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rafael Santana-Davila, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>University Hospital Antwerp</name>
      <address>
        <city>Antwerp</city>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Pol Specenier, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Grand Hopital de Chaleroi</name>
      <address>
        <city>Charleroi</city>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Christophe Lonchay, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>University Hospital Leuven</name>
      <address>
        <city>Leuven</city>
        <zip>3000</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Paul Clement, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Fakultni nemocnice Olomouc</name>
      <address>
        <city>Olomouc</city>
        <country>Czechia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Bohuslav Melichar, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Nemocnice na Bulovce</name>
      <address>
        <city>Prague</city>
        <country>Czechia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Petra Holečková, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centre Léon Bérard</name>
      <address>
        <city>Lyon</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jerome Fayette, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Fondation Hospital Saint Joseph</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michel Gatineau, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Gustave Roussy</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Caroline Even, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hopitaux Universitaires Pitié Salpêtrière Charles Foix</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Aurelien Gobert, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>University Hospital</name>
      <address>
        <city>Bonn</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Franz-Georg Bauernfeind, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>IKrankenhaus Nordwest gGmbH, nstitut für Klinisch-Onkologische Forschung</name>
      <address>
        <city>Frankfurt</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Salah-Eddin Al-Batran, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>University Hospital Leipzig</name>
      <address>
        <city>Leipzig</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Andreas Dietz, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Universitaetsklinikum Ulm</name>
      <address>
        <city>Ulm</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Simon Laban, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Magyar Honvédség Egészségügyi Központ</name>
      <address>
        <city>Budapest</city>
        <country>Hungary</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Zsuzsanna Emília Pápai, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Onkolgiai Klinika</name>
      <address>
        <city>Debrecen</city>
        <country>Hungary</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Peter Arkosy, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Petz Aladar Megyei Oktat Krhz</name>
      <address>
        <city>Gyor</city>
        <country>Hungary</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tamas Pinter, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Szabolcs Szatmar Bereg Megyei Korhazak Es Egyetemi Oktatokorhaz</name>
      <address>
        <city>Nyiregyhaza</city>
        <country>Hungary</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jozsef Erfan, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Pecs Department of Oncotherapy</name>
      <address>
        <city>Pecs</city>
        <country>Hungary</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Laszlo Mangel, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hetenyi Geza Korhaz-Rendelointezet</name>
      <address>
        <city>Szolnok</city>
        <country>Hungary</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tibor Csoszi, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliera San Paolo Polo Universitario</name>
      <address>
        <city>Milan</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Daris Ferrari, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Istituto Nazionale dei Tumori</name>
      <address>
        <city>Milan</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lisa Licitra, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>UOC Oncologia Medica Ospedale di Sondrio</name>
      <address>
        <city>Sondrio</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alessandro Bertolini, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Azienda Sanitaria Universitaria Integrata di Udine</name>
      <address>
        <city>Udine</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ciro Rossetto, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Antoni van Leeuwenhoek Ziekenhuis</name>
      <address>
        <city>Amsterdam</city>
        <zip>1066CX</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jan Paul Boer de, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Leiden University Hospital</name>
      <address>
        <city>Leiden</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marije Slingerland, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Radboud University Medical Center</name>
      <address>
        <city>Nijmegen</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Carla Herpen, van, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>University Medical Center Utrecht</name>
      <address>
        <city>Utrecht</city>
        <zip>3584 CX</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lot Devriese, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Clnic i Provincial de Barcelona</name>
      <address>
        <city>Barcelona</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Juan Grau, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Duran i Reynals - Institut Catala dOncologia ICO</name>
      <address>
        <city>Barcelona</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Miren Taberna, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Vall d'Hebron</name>
      <address>
        <city>Barcelona</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Irene Brana, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Clinico San Carlos</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Pedro Perez Segura, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario La Paz</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Beatriz Castelo Fernandez, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>The 12 de Octubre University Hospital</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Juan Antonio Núñez Sobrino, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Universitario Sanchinarro</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lisardo Ugidos de la Varga, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Virgen de la Victoria</name>
      <address>
        <city>Malaga</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jose Manuel Trigo Perez, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario de Salamanca</name>
      <address>
        <city>Salamanca</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Elvira del Barco Morillo, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Marqués de Valdecilla Santander</name>
      <address>
        <city>Santander</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Almudena Garcia Castano, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>The Royal Marsden NHS Foundation</name>
      <address>
        <city>Chelsea</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kevin Harrington, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>The Royal Marsden NHS Foundation Trust</name>
      <address>
        <city>Sutton</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kevin Harrington, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Beacon Centre Musgrove Park Hospital</name>
      <address>
        <city>Taunton</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Petra Jankowska, MD</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Belgium</country>
    <country>Czechia</country>
    <country>France</country>
    <country>Germany</country>
    <country>Hungary</country>
    <country>Italy</country>
    <country>Netherlands</country>
    <country>Spain</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2020</verification_date>
  <study_first_submitted>August 11, 2018</study_first_submitted>
  <study_first_submitted_qc>September 11, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">September 13, 2018</study_first_posted>
  <last_update_submitted>May 15, 2020</last_update_submitted>
  <last_update_submitted_qc>May 15, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">May 18, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma, Squamous Cell</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cemiplimab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

